Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$26.62
-3.3%
$29.28
$10.83
▼
$41.14
$3.54B-0.091.41 million shs1.51 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$137.75
-3.9%
$145.73
$93.90
▼
$156.92
$353.44B0.139.43 million shs9.70 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$945.53
-1.3%
$824.37
$591.52
▼
$991.73
$99.08B0.11.04 million shs705,014 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-3.27%-16.29%-2.60%-32.88%+90.82%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-3.68%-6.47%-4.06%-7.70%+42.59%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-1.28%-1.45%+20.91%+14.38%+30.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$26.62
-3.3%
$29.28
$10.83
▼
$41.14
$3.54B-0.091.41 million shs1.51 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$137.75
-3.9%
$145.73
$93.90
▼
$156.92
$353.44B0.139.43 million shs9.70 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$945.53
-1.3%
$824.37
$591.52
▼
$991.73
$99.08B0.11.04 million shs705,014 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-3.27%-16.29%-2.60%-32.88%+90.82%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-3.68%-6.47%-4.06%-7.70%+42.59%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-1.28%-1.45%+20.91%+14.38%+30.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$43.7164.22% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$155.7413.06% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.74
Moderate Buy$904.41-4.35% Downside

Current Analyst Ratings Breakdown

Latest AMLX, REGN, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price TargetOverweight$917.00 ➝ $1,075.00
11/10/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Boost Price TargetOutperform$38.00 ➝ $39.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Set Price Target$45.00
11/5/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Initiated CoverageStrong-Buy
11/3/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Reiterated RatingSell (D-)
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeBuy ➝ Hold$153.00
11/2/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UpgradeHold (C) ➝ Hold (C+)
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetHold$125.00 ➝ $140.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetNeutral$145.00 ➝ $155.00
11/2/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price TargetMarket Perform$835.00 ➝ $997.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M39.17N/AN/A$5.86 per share4.54
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.22$10.98 per share12.55$18.23 per share7.56
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B6.82$41.43 per share22.82$323.82 per share2.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.44N/AN/AN/AN/A-41.54%-38.91%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.9745.9515.176.573.64%16.73%5.88%2/2/2027 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$45.2920.8815.061.2728.51%16.01%12.22%1/28/2027 (Estimated)

Latest AMLX, REGN, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3810-$0.38+$0.0010-$0.38$0.06 millionN/A
10/30/2026Q3 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$16.51$20.07+$3.56$18.45$4.58 billion$5.12 billion
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.47%+5.75%350.52%14 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.40%N/A8.30%N/A

Latest AMLX, REGN, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/17/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.882.46%12/15/202612/15/20261/8/2027
10/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.41%11/20/202611/20/202612/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
26.81
26.81
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.35
2.89

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136128.56 million114.55 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410103.45 million96.24 millionOptionable

Recent News About These Companies

Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
Should You Pick Vertex Stock Over Its Biotech Rivals?
Regeneron wins EU nod for alternative Libtayo regimen
Can Regeneron Stock Hit $1,400?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$26.62 -0.90 (-3.27%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$27.36 +0.74 (+2.78%)
As of 11/18/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$137.75 -5.62 (-3.92%)
Closing price 11/18/2026 03:59 PM Eastern
Extended Trading
$137.60 -0.15 (-0.11%)
As of 11/18/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$945.53 -12.23 (-1.28%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$954.00 +8.47 (+0.90%)
As of 11/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.